Objective To investigate whether long non-coding RNA(LncRNA) mitochondrial RNA processing RNA endonuclease RNA component(RMRP) can inhibit lipopolysaccharide(LPS)-induced renal tubular epithelial cell injury by targeting the micro RNA(miR)-580-3p/Ras homologous gene family member A(RhoA) axis. Methods The experiment was conducted in the Central Laboratory of Jiaozhou Central Hospital of Qingdao from May to October 2024. Normally cultured human renal tubular epithelial cells HK-2 were designated as the Control group. A cell injury model was established using LPS, and the cells were divided into the Model group, sh-NC group, sh-RMRP group, sh-RMRP + anti-NC group, and shRMRP+anti-mi R-580-3p group according to different treatments. The expression levels of Lnc RNA RMRP, mi R-580-3p, and Rho A m RNA were detected by quantitative real-time PCR(qRT-PCR). The regulatory relationships between Lnc RNA RMRP and mi R-580-3p, and between mi R-580-3p and Rho A were examined by dual-luciferase assay. Cell proliferation was assessed by Cell Counting Kit-8(CCK-8) assay. The levels of interleukin-1β(IL-1β), interleukin-6(IL-6), and tumor necrosis factor-α(TNF-α) were measured by enzyme-linked immunosorbent assay(ELISA). Apoptosis was analyzed by flow cytometry. The protein expressions of Rho A, proliferating cell nuclear antigen(PCNA), B-cell lymphoma-2(Bcl-2), and Bcl-2 associated X protein(Bax) were detected by Western blot. Results Compared with the Control group, the Model group showed increased expression of Lnc RNA RMRP, Rho A m RNA and protein, apoptosis rate, IL-1β, IL-6, TNF-α, and Bax protein expression,while mi R-580-3p expression, HK-2 cell survival rate, and PCNA and Bcl-2 protein expression decreased(P<0.01). Compared with the Model group and sh-NC group, the sh-RMRP group exhibited decreased expression of Lnc RNA RMRP, Rho A m RNA and protein, apoptosis rate, IL-1β, IL-6, TNF-α, and Bax protein expression, while mi R-580-3p expression, HK-2 cell survival rate, and PCNA and Bcl-2 protein expression increased(P <0.01). Compared with the sh-RMRP group and sh-RMRP+anti-NC group, the sh-RMRP+anti-mi R-580-3p group showed increased expression of Lnc RNA RMRP, Rho A m RNA and protein, apoptosis rate, IL-1β, IL-6, TNF-α, and Bax protein expression, while mi R-580-3p expression, HK-2 cell survival rate, and PCNA and Bcl-2 protein expression decreased(P <0.01). The dual-luciferase assay showed that, compared with the mimic-NC group, the luciferase activity in the mi R-580-3p mimic group was decreased(P <0.01).Conclusion Knockdown of Lnc RNA RMRP inhibits the LPS-induced inflammatory response and apoptosis in HK-2 cells by targeting the mi R-580-3p/Rho A axis, thereby exerting a protective effect against renal tubular epithelial cell injury.

Objective To systematically evaluate the efficacy and safety of traditional Chinese medicine injection combined with conventional Western medicine for the treatment of prostate cancer patients and to provide evidence-based support for clinical practice. Methods Chinese and English databases including CNKI, Wanfang, VIP, CBM, Pub Med, and Cochrane Library were searched electronically from inception to 2024. Randomized controlled trials(RCTs) and retrospective studies comparing TCM injection combined with Western medicine versus Western medicine alone were included. The Cochrane Handbook 5.1.0 was used to assess the quality of the literature, and meta-analysis was performed using Rev Man 5.4 software. Heterogeneity was evaluated using I 2 statistics, with a fixed-effects model applied for low heterogeneity(I 2≤ 50%)and a random-effects model for high heterogeneity(I 2> 50%). Publication bias was assessed using funnel plots and Begg's test. Results A total of 20 RCTs and retrospective studies were included, comprising 1972 patients. Meta-analysis showed that:(1) The total response rate in the experimental group was significantly higher than that in the control group(MD = 2.70,95%CI :2.06-3.54,P<0.001);(2) KPS score: After treatment, the experimental group showed better improvement than the control group(MD = 2.21,95%CI :0.83-3.58,P = 0.05), with no significant difference before treatment;(3) PSA level: After treatment, the experimental group had significantly lower PSA levels than the control group(MD =-2.61,95%CI :-3.35--1.88,P <0.001), with no significant difference before treatment;(4) VAS score: Pain improvement in the experimental group was superior to that in the control group after treatment(MD =-1.02,95%CI :-1.65--0.39, P = 0.001);(5) Prostate volume: No significant difference was observed between the two groups. The overall incidence of adverse reactions in the experimental group was lower than that in the control group, though heterogeneity among studies was high(e.g., hematuria, anemia, hot flashes).Conclusion Traditional Chinese medicine injection combined with conventional Western medicine can improve the total effective rate, quality of life, and PSA levels in prostate cancer patients, with favorable safety. However, due to study heterogeneity and methodological limitations, more high-quality RCTs are needed to verify its long-term efficacy and mechanisms.

This article reports a clinical case of primary bilateral adrenal diffuse large B-cell lymphoma and provides a comprehensive literature review.

This article reports the clinical data of a pediatric patient with Denys-Drash syndrome caused by a WT1 gene variant and provides a literature review.

Stroke is characterized by acute onset and rapid progression. Early identification, early warning, and active treatment are key to improving patient prognosis. The Early Warning Score(EWS), combined with neurological deficit scores and laboratory indicators, is widely used in stroke condition assessment and treatment guidance. Both EWS and its modified versions hold significant value in predicting stroke prognosis; however, systematic reports on their application in stroke prognosis remain scarce. Additionally, intravenous thrombolysis is one of the most effective treatments within the stroke time window, yet some patients still experience poor prognosis. Understanding the prognostic factors in patients receiving intravenous thrombolysis is crucial. Nevertheless, current studies report varying results, and no unified consensus has been reached. Therefore, this article reviews the application of EWS in stroke and the factors associated with poor prognosis in patients undergoing intravenous thrombolysis, aiming to provide more evidence for stroke condition assessment and prognosis improvement.